bicalutamide has been researched along with thiohydantoins in 8 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 4 (50.00) | 24.3611 |
| 2020's | 4 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Arai, S; Ishikura, N; Kawata, H; Nakagawa, T; Nakamura, R; Nishimoto, A; Sato, H; Shiraishi, T; Tachibana, K; Yoshino, H | 1 |
| Aparicio, A; Arora, V; Bischoff, ED; Bonnefous, C; Cai, L; Cao, C; Chen, Y; Clegg, NJ; Darimont, B; De Stanchina, E; Dilhas, A; Dorow, S; Grillot, K; Hager, JH; Herbert, MR; Heyman, RA; Joseph, JD; Jung, ME; Klang, M; Ouerfelli, O; Ouk, S; Qian, J; Rix, PJ; Sawyers, CL; Scher, HI; Sensintaffar, J; Shao, G; Smith, ND; Smith-Jones, P; Tran, C; Wasielewska, T; Wongvipat, J; Wu, N; Yang, G; Zhao, H | 1 |
| Aoki, Y; Corey, E; Emura, T; Honma, A; Houjo, T; Ishikura, N; Kawata, H; Nakagawa, T; Nakamura, R; Nishimoto, A; Ohta, M; Sato, H; Shiraishi, T; Tachibana, K; Tsunenari, T; Vessella, RL; Watanabe, M; Yoshino, H | 1 |
| Fasoulaki, V; Giatromanolaki, A; Kakouratos, C; Kalamida, D; Koukourakis, MI; Mitrakas, A; Papadopoulou, E; Pouliliou, S; Xanthopoulou, E | 1 |
| Gu, Y; He, M; Peng, Y; Qu, F; Sun, J; Wang, G; Wang, Q; Zhou, F | 1 |
| Kolesar, JM; Momo, HD; Myint, ZW; Otto, DE; Wang, P; Yan, D | 1 |
| Gim, HJ; Houk, KN; Jung, ME; Park, J | 1 |
| Giatromanolaki, A; Kakouratos, C; Kalamida, D; Koukourakis, MI; Lamprou, I; Nanos, C; Xanthopoulou, E | 1 |
1 review(s) available for bicalutamide and thiohydantoins
| Article | Year |
|---|---|
Evaluation of Fall and Fracture Risk Among Men With Prostate Cancer Treated With Androgen Receptor Inhibitors: A Systematic Review and Meta-analysis.
Topics: Abiraterone Acetate; Accidental Falls; Androgen Receptor Antagonists; Anilides; Antineoplastic Agents, Hormonal; Benzamides; Case-Control Studies; Fractures, Bone; Humans; Incidence; Male; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms; Pyrazoles; Risk Factors; Thiohydantoins; Tosyl Compounds; Trauma Severity Indices | 2020 |
7 other study(ies) available for bicalutamide and thiohydantoins
| Article | Year |
|---|---|
Biological properties of androgen receptor pure antagonist for treatment of castration-resistant prostate cancer: optimization from lead compound to CH5137291.
Topics: Androgen Antagonists; Androgen Receptor Antagonists; Anilides; Animals; Antineoplastic Agents; Carbamates; Cell Nucleus; Cell Proliferation; Cells, Cultured; Dose-Response Relationship, Drug; Humans; Lead; Male; Mice; Mice, Nude; Mice, SCID; Neoplasm Transplantation; Nitriles; Orchiectomy; Prostatic Neoplasms; Receptors, Androgen; Sulfonamides; Thiohydantoins; Tosyl Compounds; Transcription, Genetic; Translocation, Genetic; Transplantation, Heterologous | 2011 |
ARN-509: a novel antiandrogen for prostate cancer treatment.
Topics: Androgen Antagonists; Anilides; Animals; Antineoplastic Agents, Hormonal; Benzamides; Cell Line, Tumor; Cell Proliferation; Gene Expression Regulation, Neoplastic; Humans; Male; Mice; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms; Rats; Receptors, Androgen; Thiohydantoins; Tosyl Compounds; Xenograft Model Antitumor Assays | 2012 |
CH5137291, an androgen receptor nuclear translocation-inhibiting compound, inhibits the growth of castration-resistant prostate cancer cells.
Topics: Anilides; Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Nucleus; Cell Proliferation; Humans; Male; Mice; Molecular Docking Simulation; Mutation; Nitriles; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Protein Transport; Receptors, Androgen; Sulfonamides; Thiohydantoins; Tosyl Compounds; Xenograft Model Antitumor Assays | 2015 |
Comparison of the effect of the antiandrogen apalutamide (ARN-509) versus bicalutamide on the androgen receptor pathway in prostate cancer cell lines.
Topics: Androgen Antagonists; Anilides; Autophagy; Cell Line, Tumor; Cell Proliferation; Gene Expression Regulation, Neoplastic; Humans; Hypoxia; Male; Nitriles; Prostate-Specific Antigen; Prostatic Neoplasms; Receptors, Androgen; Testosterone; Thiohydantoins; Tosyl Compounds | 2018 |
Metabolomic profiling to evaluate the efficacy of proxalutamide, a novel androgen receptor antagonist, in prostate cancer cells.
Topics: Amino Acids; Androgen Receptor Antagonists; Anilides; Benzamides; Cell Line, Tumor; Cell Survival; Glutathione; Humans; Male; Metabolome; Metabolomics; Nitriles; Nucleosides; Oxazoles; Phenylthiohydantoin; Prostatic Neoplasms, Castration-Resistant; Thiohydantoins; Tosyl Compounds | 2020 |
Conformational dynamics of androgen receptors bound to agonists and antagonists.
Topics: Androgen Receptor Antagonists; Androgens; Anilides; Benzamides; Binding Sites; Dihydrotestosterone; Humans; Imidazoles; Ligands; Molecular Conformation; Molecular Dynamics Simulation; Nitriles; Phenylthiohydantoin; Principal Component Analysis; Protein Binding; Protein Conformation; Receptors, Androgen; Thiohydantoins; Tosyl Compounds | 2021 |
Apalutamide radio-sensitisation of prostate cancer.
Topics: Anilides; Animals; Cell Line, Tumor; Cell Proliferation; Cell Survival; Chemoradiotherapy; Dose-Response Relationship, Radiation; Humans; Male; Mice; Nitriles; PC-3 Cells; Prostatic Neoplasms; Radiation-Sensitizing Agents; Thiohydantoins; Tosyl Compounds; Xenograft Model Antitumor Assays | 2021 |